-
-
-
-
-
-
-
FDA extends review of Praxis drug for rare epilepsy to December 2026
-
-
-
-
-
-
-
Jones Trading on Praxis Precision Medicines Inc. (PRAX): 'one step closer to becoming a commercial-stage company'
-
-
-
-
-
-
-
Here's the list of biotech stocks that have key data catalysts in 2025
15,661 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

